Clinical Trial ResultsStudy participants treated with CNM-Au8 experienced significant improvements in visual amplitude and visual latency, indicating better neurological health and potential for remyelination.
Financial HealthThe company ended the year with substantial cash reserves, providing financial runway to support ongoing operations and the continued development of CNM-Au8.
Regulatory Milestone AnticipationCNM-Au8 continues to show positive data, with analysts expecting FDA to accept its New Drug Application, potentially filling a significant market gap in the ALS therapy market.